9 February 2023: Today, the fourth edition of The Union’s desk guide for diagnosis and management of tuberculosis (TB) in children and adolescents has been published.

The World Health Organization (WHO) invites all stakeholders to comment by 9 March 2023 on the latest drafts of the target regimen profiles (TRPs) for TB treatment and the target product profiles (TPPs) for tests for TB treatment monitoring and optimization, by means of online feedback forms.

Small proteins called ferredoxins play a pivotal role in the main metabolic pathways, the series of chemical reactions occurring within a cell.

TB rivals Covid-19 as the biggest infectious disease killer of humans, claiming millions of lives each year. Now, ground-breaking research from the Universities of Warwick and Toulouse has identified a new method to help tackle this global issue.

The Stop TB Partnership released new guidance, Priority TB community, rights & gender interventions for inclusion in Global Fund applications 2023-2025, outlining six priority interventions for inclusion, and containing useful annexes on engaging in Global Fund Grant Cycle 7 processes.

Tuberculosis, humanity’s greatest infectious killer, is caused by bacteria that usually affect the lungs but can also affect many other organs in the body. In 2021, around 10.6 million people worldwide fell ill with tuberculosis (TB) and 1.6 million people died from the disease.

Researchers have discovered that over-the-counter drugs commonly used to treat heartburn could shorten the treatment of tuberculosis (TB). These drugs could also reduce the chances of the bacteria that causes TB from becoming drug resistant.

There was a significant gap in TB diagnostic care both before and during the COVID-19 pandemic among hospitalized patients with advanced HIV infection.

SEONGNAM-SI, South Korea and NEW YORK, US, February 3, 2023: Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, announced today that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.

The 2023 TB HLM Affected Communities and Civil Society Coordination Hub has been constituted to support and provide a platform for the affected communities and the civil society to engage with all processes of the upcoming 2023 UN High-Level Meeting on TB (TB HLM) scheduled for September this year in New York, USA. The Hub is hosted by the Global Fund Advocates Network (GFAN) and supported by the Stop TB Partnership.